308 related articles for article (PubMed ID: 37404304)
1. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
Li Q; Xiao X; Feng J; Yan R; Xi J
Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
[TBL] [Abstract][Full Text] [Related]
2. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
3. Cysteine-Rich Intestinal Protein 1 Served as an Epithelial Ovarian Cancer Marker via Promoting Wnt/
Liu Y; Li W; Luo J; Wu Y; Xu Y; Chen T; Zhang W; Fu F
Dis Markers; 2021; 2021():3566749. PubMed ID: 34413913
[TBL] [Abstract][Full Text] [Related]
4. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
5. Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.
Yang X; Zheng M; Ning Y; Sun J; Yu Y; Zhang S
J Transl Med; 2023 Jul; 21(1):456. PubMed ID: 37434173
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
7. Identification of immunity- and ferroptosis-related genes for predicting the prognosis of serous ovarian cancer.
Yuan X; Zhou Q; Zhang F; Zheng W; Liu H; Chen A; Tao Y
Gene; 2022 Sep; 838():146701. PubMed ID: 35777713
[TBL] [Abstract][Full Text] [Related]
8. Construction and Investigation of an LINC00284-Associated Regulatory Network in Serous Ovarian Carcinoma.
Wang S; Zhang L; Tao L; Pang L; Fu R; Fu Y; Liang W; Ding Y; Jia W
Dis Markers; 2020; 2020():9696285. PubMed ID: 32076467
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
10. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
Zhan F; Guo Y; He L
J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
[TBL] [Abstract][Full Text] [Related]
11. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
12. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA HAL suppresses the migration and invasion of serous ovarian cancer by inhibiting EMT signaling pathway.
Wu K; Li L; Li L; Wang D
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039453
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.
Li H; Wu N; Liu ZY; Chen YC; Cheng Q; Wang J
Sci Rep; 2021 Mar; 11(1):7207. PubMed ID: 33785763
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of biomarkers for epithelial-mesenchymal transition-related cells to estimate the prognosis and immune microenvironment in primary gastric cancer by the integrated analysis of single-cell and bulk RNA sequencing data.
Shen K; Ke S; Chen B; Zhang T; Wang H; Lv J; Gao W
Math Biosci Eng; 2023 Jun; 20(8):13798-13823. PubMed ID: 37679111
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
17. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
[TBL] [Abstract][Full Text] [Related]
18. Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer.
Liang H; Zhao X; Wang C; Sun J; Chen Y; Wang G; Fang L; Yang R; Yu M; Gu Y; Shan H
Mol Cancer; 2018 Jun; 17(1):96. PubMed ID: 29929545
[TBL] [Abstract][Full Text] [Related]
19. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
